GHRH-Based Peptides
Compounds such as CJC-1295, Sermorelin and Tesamorelin are related to growth hormone-releasing hormone signaling, but their structures and release characteristics differ.
Explore Dragon Pharma peptides associated with growth hormone signaling, growth hormone release and IGF-1 research. Compare individual compounds, strengths, formulations and available product documentation below.
Product Information
This category brings together Dragon Pharma products associated with growth hormone signaling, growth hormone release and the IGF-1 pathway. Although these compounds are often discussed together, they can act at different points within these biological systems and should not be treated as interchangeable.
Compounds such as CJC-1295, Sermorelin and Tesamorelin are related to growth hormone-releasing hormone signaling, but their structures and release characteristics differ.
Ipamorelin, GHRP-2, GHRP-6 and Hexarelin belong to another group of compounds studied for their interaction with pathways involved in growth hormone release.
Combination products pair compounds with complementary signaling approaches in a single formulation. Check the individual product page for the exact ingredients and strength of each component.
IGF-1 LR3 belongs to a different part of this category. It is an IGF-1 analogue rather than a growth hormone-releasing peptide, making its mechanism and research context distinct from GHRH and GHRP products.
The products in this category can be easier to compare when they are separated by how they relate to the growth hormone and IGF-1 systems. A GHRH analogue, a growth hormone secretagogue and an IGF-1 analogue are not simply different versions of the same peptide.
Start with the active compound and its product format rather than comparing products by milligram amount alone. The relevant differences can include the signaling pathway involved, peptide structure, formulation, strength and whether the vial contains one compound or a blend.
Individual product pages provide the exact active substance, vial strength, container information and available laboratory documentation, making it easier to compare similar Dragon Pharma peptides without assuming that products within the same category have identical characteristics.
Where laboratory testing is available, the corresponding product page provides the report together with details such as the test date, measured result and reported batch number. These details can be useful when comparing the report with the product being viewed.
A laboratory report applies to the submitted sample and should not be interpreted as evidence that every individual vial is identical or that a compound is safe or appropriate for a particular use.